Figure 1.

Association of APE1 protein level in NSCLC tissue and PFS and OS of patients receiving EGFR‐TKI. The expression of APE1 protein from 101 advanced NSCLC patients either carrying an activating EGFR gene mutation or with unknown EGFR gene status but with potential benefit from EGFR‐TKI was determined in biopsy tissue by IHC assay. The PFS (A) and OS (B) comparisons between different expression levels of APE1 were indicated in the Kaplan‐Meier survival curves, and the P value of each comparison was shown at the left corner